Epstein-Barr Virus gp350-ferritin Nanoparticle Vaccine with Saponin-based Adjuvant

**Semantic type:** Immunologic Factor|Pharmacologic Substance

**Definition:** A ferritin-based, nanoparticle vaccine consisting of the Epstein-Barr Virus (EBV) envelop glycoprotein gp350 and a saponin-based adjuvant, with potential immunizing activity against EBV. Upon intramuscular administration of EBV gp350-ferritin nanoparticle vaccine with saponin-based adjuvant, the EBV gp350 may activate both humoral and cellular immune responses which may result in protection against EBV infection. EBV, a ubiquitous human herpes virus, is associated with infectious mononucleosis and various malignancies, including nasopharyngeal carcinoma, Hodgkin disease, non-Hodgkin lymphoma, and other lymphomas.

**Synonyms:** - EBV gp350-based Nanoparticle Vaccine - EBV gp350-ferritin Nanoparticle Vaccine with Saponin-based Adjuvant - EBV gp350-ferritin Vaccine - EBV gp350-ferritin Vaccine/Matrix M1 - Epstein-Barr Virus gp350-ferritin Nanoparticle Vaccine with Matrix-M1 Adjuvant